Disease · EFO_0002950

pregnancy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pregnancy. Diseases, record EFO_0002950. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0002950

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pregnancy; Open Targets
Open Targets ID: EFO_0002950; Open Targets
Other names: Gestation, PREGN, Pregnancies; Open Targets
MeSH: D011247; MeSH
NCI Thesaurus: C25742; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 62 drugs, from FDA; Open Targets

Drugs62

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESTETROL	CHEMBL6068423	Small molecule	Approval	FDA	1	0	0	Drugs and targets
MISOPROSTOL	CHEMBL606	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
ETONOGESTREL	CHEMBL1531	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ETHINYL ESTRADIOL	CHEMBL691	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DINOPROSTONE	CHEMBL548	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NOLASIBAN	CHEMBL1254025	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 62

See all 62 drugs

Targets90

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	9	Progesterone receptor agonist; Progesterone receptor antagonist	Phase 3	https://conductscience.org/library/genes/5241	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	4	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Phase 3	https://conductscience.org/library/genes/2798	Drugs and targets
ESR1	Estrogen receptor	3	Estrogen receptor agonist; Estrogen receptor alpha agonist	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	3	Follicle stimulating hormone receptor agonist	Unknown	https://conductscience.org/library/genes/2492	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets

1 to 10 of 90

See all 90 targets

Trials79

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01127581	Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery	Phase 3	1,358	2014-03-07	Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor	DINOPROSTONE, MISOPROSTOL	Its record names the disease	ClinicalTrials.gov
NCT00455156	Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring	Phase 3	1,200	2026-01-23	Contraception	ETHINYL ESTRADIOL, SEGESTERONE, SEGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00702273	Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)		344	2014-11-20	In Vitro Fertilization	CORIFOLLITROPIN ALFA, FOLLITROPIN BETA, GANIRELIX, PROGESTERONE	Its record names the disease	ClinicalTrials.gov
NCT00620035	A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)	Phase 3	301	2011-10-31	Contraception	ETONOGESTREL	Its record names the disease	ClinicalTrials.gov
NCT01019369	Study of Self or Clinic Administration of DepoProvera	Not applicable	132	2015-04-15	Contraception	MEDROXYPROGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT03585504	Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents	Phase 3	81	2018-10-04	Contraceptive Usage	ETONOGESTREL	Its record names the disease	ClinicalTrials.gov
NCT03282799	Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women	Phase 2	72	2024-09-05	HIV/AIDS, Contraception	ETONOGESTREL	Its record names the disease	ClinicalTrials.gov
NCT00544882	A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021	Phase 3	61	2014-06-10	Healthy	DIENOGEST	Its record names the disease	ClinicalTrials.gov
NCT01615731	Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks	Not applicable	50	2015-01-26	Abortion, Induced	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT01636063	Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks	Not applicable	42	2017-04-07	Induced Abortion, Abortion Techniques, Mifepristone, Misoprostol	MIFEPRISTONE, MISOPROSTOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 79

See all 79 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
MVI 200 vs Dinoprostone Vaginal Insert (DVI): serious adverse events	130 of 678	107 of 680	1,358	NCT01127581	Trial comparisons
150 µg Corifollitropin Alfa vs 200 IU RecFSH: serious adverse events	1 of 168	0 of 176	344	NCT00702273	Trial comparisons
Self Administration of DMPA vs Clinic Administration of DMPA: serious adverse events	0 of 86	0 of 46	132	NCT01019369	Trial comparisons
Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA at 6 Months	61 of 86	29 of 45	131	NCT01019369	Trial comparisons
Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA	61 of 76	29 of 39	115	NCT01019369	Trial comparisons
Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: deaths from any cause	0 of 36	0 of 36	72	NCT03282799	Trial comparisons
Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: serious adverse events	0 of 36	0 of 36	72	NCT03282799	Trial comparisons
Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: Proportion of Participants That Ovulate During Month 6	17 of 35	0 of 36	71	NCT03282799	Trial comparisons
Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: Proportion of Participants That Ovulate During Month 3	11 of 35	0 of 36	71	NCT03282799	Trial comparisons
Standard Dose Etonogestrel Implant vs Increased Dose Etonogestrel Implant: Proportion of Participants That Ovulate During Month 12	19 of 34	2 of 36	70	NCT03282799	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials64

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27100512	RESULT	1	PubMed
26371706	RESULT	1	PubMed
26142620	RESULT	1	PubMed
25883442	RESULT	1	PubMed
25681385	RESULT	1	PubMed
25653897	RESULT	1	PubMed
24995856	RESULT	1	PubMed
24581729	RESULT	1	PubMed
23942472	RESULT	1	PubMed
22002012	RESULT	1	PubMed

1 to 10 of 64

See all 64 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0002950

GET https://conductscience.org/api/diseases/v1/EFO_0002950/drugs?page=2

API reference For AI assistants